Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks
Open Access
- 16 November 2012
- journal article
- research article
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 109 (12) , 2231-2239
Abstract
Despite the development of consensus-based frameworks to define cancer cachexia, the validity and usefulness of these frameworks are relatively unknown. The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III non-small-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. In forty patients at diagnosis of stage III NSCLC, weight loss, fat-free mass, handgrip strength, anorexia and serum biochemistry, assessed before the first chemotherapy, were used to define ‘cancer cachexia’ or ‘cachexia’. The cancer-specific framework also classified for pre-cachexia and refractory cachexia. Additionally, quality of life was assessed by the European Organisation for Research and Treatment of Cancer – Quality of Life Questionnaire C30. Groups were compared using independent t tests, ANOVA, Kaplan–Meier and Cox survival analyses. Based on the cancer-specific framework, pre-cachexia was present in nine patients (23 %) and cancer cachexia was present in seven patients (18 %). Cancer cachexia was associated with a reduced quality of life (P= 0·03) and shorter survival (hazard ratio (HR) = 2·9; P= 0·04). When using the general framework, cachexia was present in eleven patients (28 %), and was associated with a reduced quality of life (P= 0·08) and shorter survival (HR = 4·4; P= 0·001). In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. For both frameworks, cachexia appears to be associated with a reduced quality of life and shorter survival. Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients.Keywords
This publication has 44 references indexed in Scilit:
- Phase II Prospective Randomized Trial of a Low-Fat Diet with Fish Oil Supplementation in Men Undergoing Radical ProstatectomyCancer Prevention Research, 2011
- The cachexia score (CASCO): a new tool for staging cachectic cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Supplementation with fish oil increases first‐line chemotherapy efficacy in patients with advanced nonsmall cell lung cancerCancer, 2011
- Estimation of Cachexia among Cancer Patients Based on Four DefinitionsJournal of Oncology, 2009
- Physical Activity among Lung Cancer Survivors: Changes across the Cancer Trajectory and Associations with Quality of LifeCancer Epidemiology, Biomarkers & Prevention, 2009
- Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancerBMC Cancer, 2009
- Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancerInternational Journal of Colorectal Disease, 2007
- Cachexia and anorexia: cancer's covert killerSupportive Care in Cancer, 2000
- Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?European Journal of Cancer, 1998